Browse Studies — Arctuva

Phase 2

A Phase 2 Study of Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma

The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimer…

Relapsed or Refractory Large B-cell Lymphoma

Estimated

~$10 – $6,250

University of UtahNCT06788964

Phase 3

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractor…

Relapsed or Refractory Large B-cell Lymphoma

Estimated

~$10 – $7,500

Kite, A Gilead CompanyNCT07479797

Phase 2

A Phase 2 Study of Outpatient Epcoritamab in Large B-cell Lymphoma

The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.

Relapsed Large B-cell LymphomaRefractory Large B-cell Lymphoma

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06811272

Phase 2

Phase 2 Study of Glofitamab and Gemcitabine and Oxaliplatin (Glofit-GemOx) Bridging to Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas

The goal of this clinical trial is to assess the clinical efficacy of bridging therapy with glofitamab/gemcitabine/oxaliplatin (Glofit-GemOx) followed by lisoc…

LymphomaB-cell LymphomasRelapsed/Refractory Large B-cell Lymphoma+1 more

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07711483